Meri A. Shervashidze
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Meri A. Shervashidze has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Timur Teimurazovich Valiev
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
18 shared publications - Kirill I. Kirgizov
Research Institute of Pediatric Oncology and Hematology, FSBI “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of Russia, Kashirskoye sh. 23, Moscow 115522, Russia
9 shared publications - Svetlana R. Varfolomeeva
N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
8 shared publications - Natalia A. Batmanova
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
5 shared publications - Nikolay Nikolayevich Tupitsyn
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
5 shared publications - Natalia Andreevna Batmanova
L.A. Durnov Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
4 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (4) , 375-383
Treatment Outcomes in Children with Relapsed Acute Lymphoblastic Leukemia Using ALL-REZ BFM 2002 Protocol: Data from a Single-Center Trial
BACKGROUND. Despite considerable therapy success in newly diagnosed pediatric acute lymphoblastic leukemia (ALL), treatment of relapses remains challenging and requires a personalized approach. In the Russian Federation, the treatment of relapsed ALL is based on ALL-REZ BFM 2002, the protocol suggesting a risk-adapted strategy with assessing eligibility for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in high-risk patients. Global and national experience with implementation of this program demonstrated a therapeutic plateau, which indicates the need for modernizing the standard chemotherapy regimens and introducing novel targeted and immunological approaches. AIM. To assess the long-term outcomes of treating children with the first ALL relapse using ALL-REZ BFM 2002 at a single medical center. MATERIALS & METHODS. This study enrolled 73 patients with the confirmed diagnosis of the first ALL relapse who received a complete course of therapy according to ALL-REZ BFM 2002 at the Hematologic Malignancy Units No. 1 and No. 2 at the Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin National Medical Cancer Research Center, from 2018 to 2024. The median age was 9.3 years (range 3–17 years), most of them were boys (71 %). The data analysis was conducted as of February 1, 2026. RESULTS. The analysis of the total cohort showed the 5-year overall survival of 54.6 % and event-free survival of 48.7 % (in the S1 and S2 risk subgroups 100 % and 52.2 %, respectively). Allo-HSCT improved the 5-year disease-free survival (DFS) up to 72.5 %. The administration of targeted immunotherapy with blinatumomab or inotuzumab ozogamicin as bridge therapy prior to allo-HSCT in minimal residual disease (MRD)-positive patients resulted in further improvement of this rate up to 83.6 %. CONCLUSION. The risk-adapted ALL-REZ BFM 2002 protocol shows efficacy in patients with the first ALL relapse. Introducing blinatumomab/inotuzumab ozogamicin to achieve MRD-negative remissions prior to allo-HSCT improves DFS rates in patients with B-lineage ALL. Treatment outcomes in T-ALL patients remains poor due to high resistance to chemotherapy.
- 1 October 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (4) , 375-383
Open AccessTreatment Outcomes in Children with Relapsed Acute Lymphoblastic Leukemia Using ALL-REZ BFM 2002 Protocol: Data from a Single-Center Trial
BACKGROUND. Despite considerable therapy success in newly diagnosed pediatric acute lymphoblastic leukemia (ALL), treatment of relapses remains challenging and requires a personalized approach. In the Russian Federation, the treatment of relapsed ALL is based on ALL-REZ BFM 2002, the protocol suggesting a risk-adapted strategy with assessing eligibility for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in high-risk patients. Global and national experience with implementation of this program demonstrated a therapeutic plateau, which indicates the need for modernizing the standard chemotherapy regimens and introducing novel targeted and immunological approaches. AIM. To assess the long-term outcomes of treating children with the first ALL relapse using ALL-REZ BFM 2002 at a single medical center. MATERIALS & METHODS. This study enrolled 73 patients with the confirmed diagnosis of the first ALL relapse who received a complete course of therapy according to ALL-REZ BFM 2002 at the Hematologic Malignancy Units No. 1 and No. 2 at the Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin National Medical Cancer Research Center, from 2018 to 2024. The median age was 9.3 years (range 3–17 years), most of them were boys (71 %). The data analysis was conducted as of February 1, 2026. RESULTS. The analysis of the total cohort showed the 5-year overall survival of 54.6 % and event-free survival of 48.7 % (in the S1 and S2 risk subgroups 100 % and 52.2 %, respectively). Allo-HSCT improved the 5-year disease-free survival (DFS) up to 72.5 %. The administration of targeted immunotherapy with blinatumomab or inotuzumab ozogamicin as bridge therapy prior to allo-HSCT in minimal residual disease (MRD)-positive patients resulted in further improvement of this rate up to 83.6 %. CONCLUSION. The risk-adapted ALL-REZ BFM 2002 protocol shows efficacy in patients with the first ALL relapse. Introducing blinatumomab/inotuzumab ozogamicin to achieve MRD-negative remissions prior to allo-HSCT improves DFS rates in patients with B-lineage ALL. Treatment outcomes in T-ALL patients remains poor due to high resistance to chemotherapy.
- Open Access
- 30 June 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (2) , 138-144
Clinical use of multipotent mesenchymal stem cells in children after allogeneic bone marrow transplantation: the experience of the N.N. Blokhin National Medical Research Center of Oncology
Introduction. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the most important curative and consolidating treatment options for hematologic malignancies, immunologic diseases, and solid tumors. Nevertheless, its use may be limited due to life-threatening post-transplant complications, such as acute graft-versus-host disease (aGVHD), chronic graft-versus-host disease (cGVHD), and poor graft function. The standard treatment for these complications includes the administration of immunosuppressive drugs. However, their side effects and limited effectiveness necessitate the continued search for additional treatments, among which the use of mesenchymal stem cells (MSCs) may prove highly effective. Materials and methods. In this retrospective/prospective study conducted from 2021 to 2025, we enrolled 25 patients aged from 10 months to 16 years (with a median age of 11 years) with refractory aGVHD, cGVHD, and/or poor graft function after allo-HSCT. MSCs isolated from the bone marrow of allogeneic donors and cultured to passages 2–3 were administered intraosseously/intravenously or through a nasojejunal tube every 1–2 weeks. The primary endpoint was clinical response to therapy. Results. The median cell product dose was 20 (4–69) × 106 cells/kg recipient body weight. A response to MSC therapy was achieved in 15 (60.0%) out of 25 patients: in 8/9 (88.9%) patients with isolated poor graft function, in 4/6 patients who had both poor graft function and GVHD, and in 3/10 patients with isolated aGVHD/cGVHD. No adverse events associated with MSC administration were observed in any patient. Conclusion. The use of allogeneic MSCs in pediatric patients with refractory complications of allo-HSCT is a safe and potentially effective method. Our results are consistent with published data and warrant prospective randomized studies with a structured design and more precise response criteria.
- 30 June 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (2) , 138-144
Open AccessClinical use of multipotent mesenchymal stem cells in children after allogeneic bone marrow transplantation: the experience of the N.N. Blokhin National Medical Research Center of Oncology
Introduction. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the most important curative and consolidating treatment options for hematologic malignancies, immunologic diseases, and solid tumors. Nevertheless, its use may be limited due to life-threatening post-transplant complications, such as acute graft-versus-host disease (aGVHD), chronic graft-versus-host disease (cGVHD), and poor graft function. The standard treatment for these complications includes the administration of immunosuppressive drugs. However, their side effects and limited effectiveness necessitate the continued search for additional treatments, among which the use of mesenchymal stem cells (MSCs) may prove highly effective. Materials and methods. In this retrospective/prospective study conducted from 2021 to 2025, we enrolled 25 patients aged from 10 months to 16 years (with a median age of 11 years) with refractory aGVHD, cGVHD, and/or poor graft function after allo-HSCT. MSCs isolated from the bone marrow of allogeneic donors and cultured to passages 2–3 were administered intraosseously/intravenously or through a nasojejunal tube every 1–2 weeks. The primary endpoint was clinical response to therapy. Results. The median cell product dose was 20 (4–69) × 106 cells/kg recipient body weight. A response to MSC therapy was achieved in 15 (60.0%) out of 25 patients: in 8/9 (88.9%) patients with isolated poor graft function, in 4/6 patients who had both poor graft function and GVHD, and in 3/10 patients with isolated aGVHD/cGVHD. No adverse events associated with MSC administration were observed in any patient. Conclusion. The use of allogeneic MSCs in pediatric patients with refractory complications of allo-HSCT is a safe and potentially effective method. Our results are consistent with published data and warrant prospective randomized studies with a structured design and more precise response criteria.
- Open Access
- 31 January 2026
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 1,p. 155-163
Risk factors for malnutrition in children with cancer: a prospective cohort study
INTRODUCTION: Malnutrition is detected in 10–50 % of children with cancer. Providing adequate nutritional therapy in pediatric oncology is a complex task that requires systematic screening, timely nutritional interventions and assessment of their effectiveness at different stages of antitumor treatment. OBJECTIVE: To determine the prevalence of severe protein-energy malnutrition (PEM) in children receiving treatment for malignant neoplasms and to identify factors associated with the development of severe PEM. MATERIALS AND METHODS: A prospective, single-center, continuous cohort study was conducted from January 2023 to January 2024 at the Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin National Medical Research Center of Oncology, among children aged 0 to 18 years with malignant neoplasms. RESULTS: Data from 3,455 children were analyzed, including 1,754 (50.8 %) boys and 1,701 (49.2 %) girls. Moderate or mild PEM was diagnosed in 635 (18 %) patients at stage 1 nutritional screening. At stage 2 screening, after the start of antitumor treatment, severe PEM was identified in 102 (3 %) children. There was a strong positive correlation between moderate and mild PEM at stage 1 and the subsequent development of severe PEM after treatment initiation (Kendall’s Τ = 0.69, Tcrit = 0.23). The odds of severe PEM were higher in children under 1 year of age than in those aged 1–18 years (odds ratio [OR] 5.868; 95 % confidence interval [CI] 2.985–11.500; standard error [SE] 0.345). Severe PEM was more likely in patients with solid malignant tumors than in those with hematologic malignancies (OR 3.14; 95% CI 1.60–6.08; SE 0.337). Among patients after hematopoietic stem cell transplantation, the probability of developing severe PEM was also higher (OR 5.3; 95% CI 2.80–9.76; SE 0.3). CONCLUSIONS: Severe PEM after the start of treatment was observed in 3 % of pediatric patients with cancer. Factors contributing to its development were: first moderate and mild PEM, age under 1-year, solid tumors, hematopoietic stem cell transplantation.
- 31 January 2026
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 1,p. 155-163
Open AccessRisk factors for malnutrition in children with cancer: a prospective cohort study
INTRODUCTION: Malnutrition is detected in 10–50 % of children with cancer. Providing adequate nutritional therapy in pediatric oncology is a complex task that requires systematic screening, timely nutritional interventions and assessment of their effectiveness at different stages of antitumor treatment. OBJECTIVE: To determine the prevalence of severe protein-energy malnutrition (PEM) in children receiving treatment for malignant neoplasms and to identify factors associated with the development of severe PEM. MATERIALS AND METHODS: A prospective, single-center, continuous cohort study was conducted from January 2023 to January 2024 at the Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin National Medical Research Center of Oncology, among children aged 0 to 18 years with malignant neoplasms. RESULTS: Data from 3,455 children were analyzed, including 1,754 (50.8 %) boys and 1,701 (49.2 %) girls. Moderate or mild PEM was diagnosed in 635 (18 %) patients at stage 1 nutritional screening. At stage 2 screening, after the start of antitumor treatment, severe PEM was identified in 102 (3 %) children. There was a strong positive correlation between moderate and mild PEM at stage 1 and the subsequent development of severe PEM after treatment initiation (Kendall’s Τ = 0.69, Tcrit = 0.23). The odds of severe PEM were higher in children under 1 year of age than in those aged 1–18 years (odds ratio [OR] 5.868; 95 % confidence interval [CI] 2.985–11.500; standard error [SE] 0.345). Severe PEM was more likely in patients with solid malignant tumors than in those with hematologic malignancies (OR 3.14; 95% CI 1.60–6.08; SE 0.337). Among patients after hematopoietic stem cell transplantation, the probability of developing severe PEM was also higher (OR 5.3; 95% CI 2.80–9.76; SE 0.3). CONCLUSIONS: Severe PEM after the start of treatment was observed in 3 % of pediatric patients with cancer. Factors contributing to its development were: first moderate and mild PEM, age under 1-year, solid tumors, hematopoietic stem cell transplantation.
- Open Access
- 14 January 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (4) , 89-96
Problems of therapy and search for curative options in infantile acute B-cell lymphoblastic leukemia: a clinical case
Infantile acute B-cell lymphoblastic leukemia (B-ALL) is a rare leukemia that develops in children of the first year of life, prone to an aggressive course, a combination of unfavorable prognostic factors, frequent relapses and “switching” of tumor cell differentiation from lymphoid to myeloid. In addition, the physiological features and high vulnerability of the infant's body to the influence of unfavorable external factors cause a high frequency of severe complications of both the underlying disease and the specific treatment, which limits the possibilities of therapy and reduces the likelihood of a favorable outcome in such patients. In this regard, there is no doubt that the search for new curative options that increase the effectiveness and reduce the toxicity of therapy for B-ALL in infants is highly relevant. Given the rarity of this type of leukemia, fundamental studies of the biology of infantile leukemia, extensive clinical trials, and exchange of experience between transplant centers involved in the treatment of such patients are important for improving the effectiveness of its therapy. The clinical case presented in this article demonstrates the main problems of therapy for infantile B-ALL: the initial presence of a set of unfavorable prognostic factors (MLL gene rearrangement, lack of CD10 expression on tumor cells, age under 3 months, hyperleukocytosis, and central nervous system damage at manifestation), “switching” of the blast cell line from lymphoid to myeloid, poor response to glucocorticosteroids and development of severe complications limiting the possibilities of therapy intensification already at the stage of induction therapy, refractory course, relapse at late stages after allogeneic hematopoietic stem cell transplantation. Moreover, an individualized approach and the use of new treatment methods, including immunotherapy, cell therapy and apoptosis inducers, allowed the patient to achieve clinical and hematological remission with negative minimal residual disease a year after allogeneic hematopoietic stem cell transplantation, even after a relapse of leukemia.
- 14 January 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (4) , 89-96
Open AccessProblems of therapy and search for curative options in infantile acute B-cell lymphoblastic leukemia: a clinical case
Infantile acute B-cell lymphoblastic leukemia (B-ALL) is a rare leukemia that develops in children of the first year of life, prone to an aggressive course, a combination of unfavorable prognostic factors, frequent relapses and “switching” of tumor cell differentiation from lymphoid to myeloid. In addition, the physiological features and high vulnerability of the infant's body to the influence of unfavorable external factors cause a high frequency of severe complications of both the underlying disease and the specific treatment, which limits the possibilities of therapy and reduces the likelihood of a favorable outcome in such patients. In this regard, there is no doubt that the search for new curative options that increase the effectiveness and reduce the toxicity of therapy for B-ALL in infants is highly relevant. Given the rarity of this type of leukemia, fundamental studies of the biology of infantile leukemia, extensive clinical trials, and exchange of experience between transplant centers involved in the treatment of such patients are important for improving the effectiveness of its therapy. The clinical case presented in this article demonstrates the main problems of therapy for infantile B-ALL: the initial presence of a set of unfavorable prognostic factors (MLL gene rearrangement, lack of CD10 expression on tumor cells, age under 3 months, hyperleukocytosis, and central nervous system damage at manifestation), “switching” of the blast cell line from lymphoid to myeloid, poor response to glucocorticosteroids and development of severe complications limiting the possibilities of therapy intensification already at the stage of induction therapy, refractory course, relapse at late stages after allogeneic hematopoietic stem cell transplantation. Moreover, an individualized approach and the use of new treatment methods, including immunotherapy, cell therapy and apoptosis inducers, allowed the patient to achieve clinical and hematological remission with negative minimal residual disease a year after allogeneic hematopoietic stem cell transplantation, even after a relapse of leukemia.
- Open Access
- 8 December 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (4) , 44-51
Native and pegylated forms of L-asparaginase: the assessment of effectiveness and toxicity in acute lymphoblastic leukemia treated with Berlin–Frankfurt–Munster (BFM) protocol
Background. L-asparaginase is an integral part of chemotherapy regimens in treatment of patients with acute lymphoblastic leukemia (ALL). However, the use of L-asparaginase is limited due to wide range of adverse reactions. Our research demonstrates the toxicity effects and treatment results in patients with ALL who received native and pegylated (EG) L-asparaginase.Materials and methods. From 2013 to 2023 in the study 199 patients with newly diagnosed ALL were enrolled. Patients were treated according to the ALL IC-BFM 2009 protocol including L-asparaginase. The average age of patients was 4.6 (1–18) years. B-ALL was diagnosed in 175 (87.9 %) patients, T-ALL in 24 (12.1 %) patients. Native L-asparaginase was used in the therapy of 51 (25.6 %) patients; if allergic reactions occured, 72 (36.2 %) patients received EG asparaginase. In 76 (38.2 %) patients treatment protocol included only EG-asparaginase without native L-asparaginase history.Results. The most common adverse event was a hypersensitivity reaction – 27.6 % (n = 55), which was more common in the cohort of patients receiving native L-asparaginase. The incidence of hypercoagulation for patients treated with native L-asparaginase was 4 % and 0 % – for EG-asparaginase group. Hypocoagulation, presented as hypofibrinogenemia registered in 13 % of patients received native L-asparaginase and in 35 % for EG-asparaginase group. ancreatitis, complicated ALL treatment were diagnosed in 4 % after native L-asparaginase and 1 % after EG-asparaginase. The best 5‑year survival rates were observed in the group of patients who initially received EG-asparaginase – overall and eventfree survival were 100 and 87.5 (11.7) %, respectively (р 0.05).Conclusion. Despite the absence of convincing survival benefit in patients with newly diagnosed ALL treated with EG-asparaginase, the toxicity profile was better in contrast to native L-asparaginase.
- 8 December 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (4) , 44-51
Open AccessNative and pegylated forms of L-asparaginase: the assessment of effectiveness and toxicity in acute lymphoblastic leukemia treated with Berlin–Frankfurt–Munster (BFM) protocol
Background. L-asparaginase is an integral part of chemotherapy regimens in treatment of patients with acute lymphoblastic leukemia (ALL). However, the use of L-asparaginase is limited due to wide range of adverse reactions. Our research demonstrates the toxicity effects and treatment results in patients with ALL who received native and pegylated (EG) L-asparaginase.Materials and methods. From 2013 to 2023 in the study 199 patients with newly diagnosed ALL were enrolled. Patients were treated according to the ALL IC-BFM 2009 protocol including L-asparaginase. The average age of patients was 4.6 (1–18) years. B-ALL was diagnosed in 175 (87.9 %) patients, T-ALL in 24 (12.1 %) patients. Native L-asparaginase was used in the therapy of 51 (25.6 %) patients; if allergic reactions occured, 72 (36.2 %) patients received EG asparaginase. In 76 (38.2 %) patients treatment protocol included only EG-asparaginase without native L-asparaginase history.Results. The most common adverse event was a hypersensitivity reaction – 27.6 % (n = 55), which was more common in the cohort of patients receiving native L-asparaginase. The incidence of hypercoagulation for patients treated with native L-asparaginase was 4 % and 0 % – for EG-asparaginase group. Hypocoagulation, presented as hypofibrinogenemia registered in 13 % of patients received native L-asparaginase and in 35 % for EG-asparaginase group. ancreatitis, complicated ALL treatment were diagnosed in 4 % after native L-asparaginase and 1 % after EG-asparaginase. The best 5‑year survival rates were observed in the group of patients who initially received EG-asparaginase – overall and eventfree survival were 100 and 87.5 (11.7) %, respectively (р 0.05).Conclusion. Despite the absence of convincing survival benefit in patients with newly diagnosed ALL treated with EG-asparaginase, the toxicity profile was better in contrast to native L-asparaginase.
- Open Access
- 6 December 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (4) , 23-31
The role of high-dose methotrexate in T-cell acute lymphoblastic leukemia treatment: multicenter study results of ALL IC-BFM 2002 protocol
Backround. A progress in Tcell acute lymphoblastic leukemia (TALL) treatment has been achieved in recent years by use a combination of riskadopted chemoradiation therapy, based on highdose (5000 mg/m2) methotrexate. A prerequisite for successful therapy is carefully follow supportive care principles and recommendations, which include blood serum methotrexate concentration monitoring, leucovorin rescue and alkaline solutions use for the best methotrexate elimination and decrease its toxic effects.Aim. To assess the effectiveness of ALL ICFM 2002 protocol based on highdose methotrexate for Tcell acute lymphoblastic leukemia.Materials and methods. From 2003 to 2023 in retroprospective study 67 patients with primary diagnosed TALL were enrolled. Median age was 7.4 years (from 0 to 18 years). All the patients were treated according to riskadopted ALL ICFM 2002 protocol. The therapy efficacy was assessed by overall (OS), eventfree (EFS) and relapsefree survival analysis. The survival rates were calculated with statistic program SSS 21.0 by Kaplan–Meier method.Results. The use of highdose methotrexate for TALL treatment in ALL ICFM 2002 protocol secure high survival rates: 10‑year OS was 82.5 ± 3 %, EFS – 79.3 ± 3 %. Analyzing OS and EFS depending on prognostic risk group we found that standard risk patients had OS and EFS 85.4 ± 6.9 and 78.4 ± 8 %, intermediate – 85.6 ± 6.7 and 82 ± 7.3 % and highrisk – 34.6 ± 18.3 and 20.8 ± 17.1 % respectively (р 0.05).Conclusion. ALL ICFM 2002 protocol for TALL includes highdose (5000 mg/m2) methotrexate is an effective for standard and intermediate risk patients, but for TALL patients with unfavorable prognostic factors it is necessary a therapy modification by additional cytotoxic and targeted options (nelarabine and daratumumab) inclusion and widening the indications for allogeneic stem cell transplantation.
- 6 December 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (4) , 23-31
Open AccessThe role of high-dose methotrexate in T-cell acute lymphoblastic leukemia treatment: multicenter study results of ALL IC-BFM 2002 protocol
Backround. A progress in Tcell acute lymphoblastic leukemia (TALL) treatment has been achieved in recent years by use a combination of riskadopted chemoradiation therapy, based on highdose (5000 mg/m2) methotrexate. A prerequisite for successful therapy is carefully follow supportive care principles and recommendations, which include blood serum methotrexate concentration monitoring, leucovorin rescue and alkaline solutions use for the best methotrexate elimination and decrease its toxic effects.Aim. To assess the effectiveness of ALL ICFM 2002 protocol based on highdose methotrexate for Tcell acute lymphoblastic leukemia.Materials and methods. From 2003 to 2023 in retroprospective study 67 patients with primary diagnosed TALL were enrolled. Median age was 7.4 years (from 0 to 18 years). All the patients were treated according to riskadopted ALL ICFM 2002 protocol. The therapy efficacy was assessed by overall (OS), eventfree (EFS) and relapsefree survival analysis. The survival rates were calculated with statistic program SSS 21.0 by Kaplan–Meier method.Results. The use of highdose methotrexate for TALL treatment in ALL ICFM 2002 protocol secure high survival rates: 10‑year OS was 82.5 ± 3 %, EFS – 79.3 ± 3 %. Analyzing OS and EFS depending on prognostic risk group we found that standard risk patients had OS and EFS 85.4 ± 6.9 and 78.4 ± 8 %, intermediate – 85.6 ± 6.7 and 82 ± 7.3 % and highrisk – 34.6 ± 18.3 and 20.8 ± 17.1 % respectively (р 0.05).Conclusion. ALL ICFM 2002 protocol for TALL includes highdose (5000 mg/m2) methotrexate is an effective for standard and intermediate risk patients, but for TALL patients with unfavorable prognostic factors it is necessary a therapy modification by additional cytotoxic and targeted options (nelarabine and daratumumab) inclusion and widening the indications for allogeneic stem cell transplantation.
- Open Access
- 27 January 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (1) , 113-124
Successful treatment of pancreatitis caused by L-asparaginase in clinical practice
Treatment intensification of acute lymphoblastic leukemia in children with L-asparaginase (L-ASP) improves therapy effectiveness and shows high survival rates. The unique biological properties of this enzyme make it possible to suppress tumor blasts proliferation by reducing blood asparagine concentration. L-ASP use is limited by toxicity and hypersensitivity reactions observed in 75 % of cases. Although most complications during L-ASP therapy are mild/moderate and are manageable with adequate accompanying therapy, the development of severe side effects leads to forced withdrawal of L-ASP, which significantly reduces the likelihood of a favorable outcome in children with acute lymphoblastic leukemia. One of the most severe toxicity manifestations is the development of asparaginase-associated pancreatitis. It worsens the prognosis and may cause patients’ death. This article presents both current data about asparaginase-associated pancreatitis and treatment experience of this complication at the Research Institute of Pediatric Oncology and Hematology of the N. N. Blokhin National Research Center of Oncology.
- 27 January 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (1) , 113-124
Open AccessSuccessful treatment of pancreatitis caused by L-asparaginase in clinical practice
Treatment intensification of acute lymphoblastic leukemia in children with L-asparaginase (L-ASP) improves therapy effectiveness and shows high survival rates. The unique biological properties of this enzyme make it possible to suppress tumor blasts proliferation by reducing blood asparagine concentration. L-ASP use is limited by toxicity and hypersensitivity reactions observed in 75 % of cases. Although most complications during L-ASP therapy are mild/moderate and are manageable with adequate accompanying therapy, the development of severe side effects leads to forced withdrawal of L-ASP, which significantly reduces the likelihood of a favorable outcome in children with acute lymphoblastic leukemia. One of the most severe toxicity manifestations is the development of asparaginase-associated pancreatitis. It worsens the prognosis and may cause patients’ death. This article presents both current data about asparaginase-associated pancreatitis and treatment experience of this complication at the Research Institute of Pediatric Oncology and Hematology of the N. N. Blokhin National Research Center of Oncology.
- Open Access
- 22 August 2023
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 20 (4) , 303-308
Antileukemic impact of glucocorticoid use in acute lymphoblastic leukaemia treatment
Glucocorticoids (GC) are used as anti-inflammatory, immunosupressive and anti-tumor agents for several decades due to their ability to cell cycle inhibition and apoptosis induction but mechanism of action is not fully explored. Glucocorticoids play one of the key roles in acute lymphoblastic leukaemia treatment and are at the forefront in induction and reinduction phases. The response of tumor clone to GC determines a risk group and prognosis. A number of mechanisms of antileukemic action and resistance factors will be describe in this article.
- 22 August 2023
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 20 (4) , 303-308
Open AccessAntileukemic impact of glucocorticoid use in acute lymphoblastic leukaemia treatment
Glucocorticoids (GC) are used as anti-inflammatory, immunosupressive and anti-tumor agents for several decades due to their ability to cell cycle inhibition and apoptosis induction but mechanism of action is not fully explored. Glucocorticoids play one of the key roles in acute lymphoblastic leukaemia treatment and are at the forefront in induction and reinduction phases. The response of tumor clone to GC determines a risk group and prognosis. A number of mechanisms of antileukemic action and resistance factors will be describe in this article.
- Open Access
- 23 November 2022
- Published by Alfmed LLC in Medical alphabet
- No. 26,p. 31-34
Minimal residual disease in B-precursor acute lymphoblastic leukemia: Clinical significance on post-induction treatment
Minimal residual disease (MRD) assessment in patients with acute lymphoblastic leukemia (ALL) became an integral part of total evaluation of chemotherapy efficacy. No doubt, that it is necessary to evaluate MRD at remission induction and before allogenic stem cell transplantation, but MRD prognostic role at post-induction treatment is on-study.Aim. To evaluate a prognostic significance of MRD at post-induction treatment in pediatric patients with ALL.Materials and methods. From October 2010 to September 2022, there were 142 pediatric patients with primary diagnosed B-precursor ALL enrolled the study. All the patients were treated by ALL–IC BFM 2009 protocol.Results. 6-year overall survival (OS) for patients with MRD-positive status at post-induction treatment (78th day of therapy) was 90.8 ± 4.0 %, with MRD-negative – 91,1 ± 3.9 % (р = 0,8). Relapse-free survival (RFS) for MRD-positive – 67.4 ± 11.6 %, MRD-negative – 88.9 ± 4.3 % (р = 0,03). Event-free survival for MRD-positive – 67.4 ± 11.6 %, MRD-negative – 87,5 ± 4.5 % (р = 0,06).Conclusion. MRD level at induction remission treatment is an important risk-stratified factor in pediatric patients with ALL, but prognostic significance of MRD at post-induction therapy is under investigation. Presented our data showed increased relapse incidence on 21.5 % in patients with MRDpositive status at 78th day of therapy. OS was the same and not depended on post-induction MRD-level.
- 23 November 2022
- Published by Alfmed LLC in Medical alphabet
- No. 26,p. 31-34
Open AccessMinimal residual disease in B-precursor acute lymphoblastic leukemia: Clinical significance on post-induction treatment
Minimal residual disease (MRD) assessment in patients with acute lymphoblastic leukemia (ALL) became an integral part of total evaluation of chemotherapy efficacy. No doubt, that it is necessary to evaluate MRD at remission induction and before allogenic stem cell transplantation, but MRD prognostic role at post-induction treatment is on-study.Aim. To evaluate a prognostic significance of MRD at post-induction treatment in pediatric patients with ALL.Materials and methods. From October 2010 to September 2022, there were 142 pediatric patients with primary diagnosed B-precursor ALL enrolled the study. All the patients were treated by ALL–IC BFM 2009 protocol.Results. 6-year overall survival (OS) for patients with MRD-positive status at post-induction treatment (78th day of therapy) was 90.8 ± 4.0 %, with MRD-negative – 91,1 ± 3.9 % (р = 0,8). Relapse-free survival (RFS) for MRD-positive – 67.4 ± 11.6 %, MRD-negative – 88.9 ± 4.3 % (р = 0,03). Event-free survival for MRD-positive – 67.4 ± 11.6 %, MRD-negative – 87,5 ± 4.5 % (р = 0,06).Conclusion. MRD level at induction remission treatment is an important risk-stratified factor in pediatric patients with ALL, but prognostic significance of MRD at post-induction therapy is under investigation. Presented our data showed increased relapse incidence on 21.5 % in patients with MRDpositive status at 78th day of therapy. OS was the same and not depended on post-induction MRD-level.
- Open Access
- 8 November 2022
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 9 (3) , 32-41
Pediatric acute lymphoblastic leukemia: multicenter study of the treatment by the protocol ALL IC-BFM 2002
Background. Recovery of children with acute lymphoblastic leukemia (ALL) was one of the most significant achievements of clinical oncohematology of XX century. Success in the treatment of ALL became possible due to comprehensive (clinical, morphoimmunological, cytogenetic) diagnostics and the development of differentiated, risk-adapted treatment protocols. The German group BFM (Berlin–Frankfurt–Munster) became a pioneer in creating effective treatment programs for children with ALL. Its new principles and approaches in treatment allow the vast majority of patients to be cured.The aim of the study – presentation of the treatment results of children with ALL based on the ALL IC-BFM 2002 protocol as part of a multicenter long standing study.Materials and methods. There were 592 patients with a newly diagnosed ALL in the study . The average age of patients was 10.5 years (from 4 months to 21 years). Treatment was carried out according to the ALL IC-BFM 2002 protocol in 11 clinics from 01.11.2003 to 16.05.2022. The overall (OS), relapse-free (RFS) and event-free (EFS) survivals of patients were estimated on 01.07.2022.Results. Complete clinical and hematological remission was achieved by the 33 day of therapy in 582 (98.3 %) cases. 10-year OS was 90.4 ± 1.5 %, RFS – 83.9 ± 1.9 % EFS – 82.4 ± 1.9 %. The analysis of survival of ALL patients in prognostic risk groups showed that 10-year OS in the standard risk group was 92.8 ± 1.7 %, RFS – 86 ± 2.2 % and EFS – 84.3 ± 2.2 %. Among the patients of the intermediate risk group the OS, RFS and EFS were 94.6 ± 2.6 %, 82.2 ± 5 % and 81.7 ± 5 %, respectively. The prognosis of ALL patients from the high-risk group turned out to be the least favorable: OS was 69.5 ± 8.7 %, RFS – 62 ± 9.4 % and EFS – 60.3 ± 9.3 %.Conclusion. Based on the results of a multicenter study the ALL IC-BFM 2002 protocol showed high efficiency with the possibility of achieving a 10-year OS of 90.4 ± 1.5 %. This protocol turned out to be reproducible both in federal and regional clinics with high rates of long-term patients survival. This fact allows including it in the clinical recommendations of the Ministry of Health of Russia.
- 8 November 2022
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 9 (3) , 32-41
Open AccessPediatric acute lymphoblastic leukemia: multicenter study of the treatment by the protocol ALL IC-BFM 2002
Background. Recovery of children with acute lymphoblastic leukemia (ALL) was one of the most significant achievements of clinical oncohematology of XX century. Success in the treatment of ALL became possible due to comprehensive (clinical, morphoimmunological, cytogenetic) diagnostics and the development of differentiated, risk-adapted treatment protocols. The German group BFM (Berlin–Frankfurt–Munster) became a pioneer in creating effective treatment programs for children with ALL. Its new principles and approaches in treatment allow the vast majority of patients to be cured.The aim of the study – presentation of the treatment results of children with ALL based on the ALL IC-BFM 2002 protocol as part of a multicenter long standing study.Materials and methods. There were 592 patients with a newly diagnosed ALL in the study . The average age of patients was 10.5 years (from 4 months to 21 years). Treatment was carried out according to the ALL IC-BFM 2002 protocol in 11 clinics from 01.11.2003 to 16.05.2022. The overall (OS), relapse-free (RFS) and event-free (EFS) survivals of patients were estimated on 01.07.2022.Results. Complete clinical and hematological remission was achieved by the 33 day of therapy in 582 (98.3 %) cases. 10-year OS was 90.4 ± 1.5 %, RFS – 83.9 ± 1.9 % EFS – 82.4 ± 1.9 %. The analysis of survival of ALL patients in prognostic risk groups showed that 10-year OS in the standard risk group was 92.8 ± 1.7 %, RFS – 86 ± 2.2 % and EFS – 84.3 ± 2.2 %. Among the patients of the intermediate risk group the OS, RFS and EFS were 94.6 ± 2.6 %, 82.2 ± 5 % and 81.7 ± 5 %, respectively. The prognosis of ALL patients from the high-risk group turned out to be the least favorable: OS was 69.5 ± 8.7 %, RFS – 62 ± 9.4 % and EFS – 60.3 ± 9.3 %.Conclusion. Based on the results of a multicenter study the ALL IC-BFM 2002 protocol showed high efficiency with the possibility of achieving a 10-year OS of 90.4 ± 1.5 %. This protocol turned out to be reproducible both in federal and regional clinics with high rates of long-term patients survival. This fact allows including it in the clinical recommendations of the Ministry of Health of Russia.